Lindinet 20 tablets 0.075 + 0.02mg, No. 21

Contraception.

Inside, without chewing, drinking plenty of water, regardless of the meal.

Take 1 table. per day (if possible at the same time of day) for 21 days. Then, after taking a 7-day break in taking the pills, resume oral contraception (i.e. 4 weeks after taking the 1st tablet, on the same day of the week). During the 7-day break, uterine bleeding occurs as a result of hormone withdrawal.

The first intake of the drug: taking the drug Lindinet 20 should be started from the 1st to the 5th day of the menstrual cycle.

The transition from a combined oral contraceptive to taking the drug Lindinet 20. 1st table. Lindinet 20 is recommended to be taken after taking the last hormone-containing pill of the previous drug, on the 1st day of withdrawal bleeding.

The transition from progestogen-containing drugs (mini-tablets, injections, implants) to taking Lindinet 20. The transition from mini-tablets can be started on any day of the menstrual cycle; in the case of an implant - the next day after its removal; in case of injections - on the eve of the last injection.

Moreover, in the first 7 days of taking Lindinet 20, an additional method of contraception must be used.

Taking Lindinet 20 after an abortion in the first trimester of pregnancy. Contraceptive use can be started immediately after an abortion, without the need for an additional method of contraception.

Taking Lindinet 20 after childbirth or after an abortion in the second trimester of pregnancy. Contraceptive use can be started on the 21-28th day after childbirth or abortion in the second trimester of pregnancy. At a later start of taking a contraceptive, in the first 7 days, it is necessary to use an additional, barrier method of contraception. In the case when sexual contact took place before the start of contraception, before starting to take the drug, you should exclude the presence of a new pregnancy or wait for the next menstruation.

Missed pills. If the next scheduled pill intake was missed, then the missed dose should be replenished as soon as possible. With a delay not exceeding 12 hours, the contraceptive effect of the drug does not decrease, and there is no need to use an additional method of contraception. The rest of the pills are taken as usual.

For more than 12 hours, the contraceptive effect may be reduced. In such cases, you should not replenish the missed dose, continue taking the drug as usual, but in the next 7 days it is necessary to use an additional method of contraception. If, at the same time, less than 7 tablets remained in the package, then they start taking the tablets from the next package without observing a break. In such cases, withdrawal uterine bleeding occurs only after the completion of the 2nd package; while taking pills from the 2nd package, spotting or breakthrough bleeding is possible.

If, at the end of taking the pills from the 2nd package, withdrawal bleeding does not occur, then pregnancy should be excluded before continuing to take the contraceptive.

Measures to be taken in case of vomiting and diarrhea. If vomiting occurs in the first 3-4 hours after taking the next tablet, the tablet is not completely absorbed. In such cases, you should proceed according to the directions described in the Missed tablets section.

If the patient does not want to deviate from the usual contraceptive regimen, the missed pills should be taken from a different package.

Delay of menstruation and acceleration of the onset of menstruation. In order to delay menstruation, they start taking pills from a new package without observing a break. Menstruation can be delayed as desired until all pills from the 2nd package are gone. With a delay in menstruation, breakthrough or spotting uterine bleeding is possible. You can return to the usual pill intake after observing the 7-day break.

For an earlier onset of menstrual bleeding, you can shorten the 7-day break by the desired number of days. The shorter the break, the more likely it is that breakthrough or spotting bleeding will occur while taking the tablets from the next pack (similar to cases with delayed menstruation).

individual hypersensitivity to the drug or its components;

the presence of severe or multiple risk factors for venous or arterial thrombosis (including complicated lesions of the valvular apparatus of the heart, atrial fibrillation, diseases of the vessels of the brain or coronary arteries);

uncontrolled arterial hypertension of moderate or severe degree with blood pressure 160/100 mm Hg. Art. and more);

precursors of thrombosis (including transient ischemic attack, angina pectoris), incl. history;

migraine with focal neurological symptoms, incl. history;

venous or arterial thrombosis / thromboembolism (including deep vein thrombosis of the leg, pulmonary embolism, myocardial infarction, stroke) at present or history;

the presence of venous thromboembolism in relatives;

serious surgical intervention with prolonged immobilization;

diabetes mellitus (with the presence of angiopathy);

pancreatitis (including history), accompanied by severe hypertriglyceridemia;

dyslipidemia;

severe liver disease, cholestatic jaundice (including during pregnancy), hepatitis, incl. in the anamnesis (before the normalization of functional and laboratory parameters and within 3 months after the return of these indicators to normal);

jaundice due to the intake of drugs containing steroids;

gallstone disease at present or history;

Gilbert's syndrome, Dubin-Johnson, Rotor;

liver tumors (including history);

severe itching, otosclerosis or progression of otosclerosis during a previous pregnancy or when taking corticosteroids;

hormone-dependent malignant neoplasms of the genitals and mammary glands (including suspicion of them);

vaginal bleeding of unknown etiology;

smoking over the age of 35 (more than 15 cigarettes per day);

pregnancy or suspicion of it;

lactation.

With caution: conditions that increase the risk of developing venous or arterial thrombosis / thromboembolism (age over 35, smoking, hereditary predisposition to thrombosis - thrombosis, myocardial infarction or cerebrovascular accident at a young age in one of the closest relatives); hemolytic uremic syndrome; hereditary angioedema; liver disease; diseases that first appeared or worsened during pregnancy or against the background of previous intake of sex hormones (including porphyria, herpes of pregnant women, chorea minor - Sydenham's disease, Sydenham's chorea, chloasma); obesity (body mass index over 30); dyslipoproteinemia; arterial hypertension; migraine; epilepsy; valvular heart disease; atrial fibrillation; prolonged immobilization; extensive surgical intervention;surgery on the lower extremities; severe injury; varicose veins and superficial thrombophlebitis; postpartum period (non-lactating women - 21 days after childbirth; lactating women - after the end of the lactation period); the presence of severe depression, incl. history; changes in biochemical parameters (resistance of activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C or S deficiency, antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant); diabetes mellitus, not complicated by vascular disorders; systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.varicose veins and superficial thrombophlebitis; postpartum period (non-lactating women - 21 days after childbirth; lactating women - after the end of the lactation period); the presence of severe depression, incl. history; changes in biochemical parameters (resistance of activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C or S deficiency, antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant); diabetes mellitus, not complicated by vascular disorders; systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.varicose veins and superficial thrombophlebitis; postpartum period (non-lactating women - 21 days after childbirth; lactating women - after the end of the lactation period); the presence of severe depression, incl. history; changes in biochemical parameters (resistance of activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C or S deficiency, antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant); diabetes mellitus, not complicated by vascular disorders; systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.the presence of severe depression, incl. history; changes in biochemical parameters (resistance of activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C or S deficiency, antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant); diabetes mellitus, not complicated by vascular disorders; systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.the presence of severe depression, incl. history; changes in biochemical parameters (resistance of activated protein C, hyperhomocysteinemia, antithrombin III deficiency, protein C or S deficiency, antiphospholipid antibodies, including antibodies to cardiolipin, lupus anticoagulant); diabetes mellitus, not complicated by vascular disorders; systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.systemic lupus erythematosus (SLE); Crohn's disease; ulcerative colitis; sickle cell anemia; hypertriglyceridemia (including family history); acute and chronic liver diseases.